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On February 3, 2010, a “Letter of Concern from Bioethicists,” organized by fetaldex.org was sent to
report suspected violations of the ethics of human subjects research in the off-label use of
dexamethasone during pregnancy by Dr. Maria New. Copies of this letter were submitted to the FDA
Office of Pediatric Therapeutics, the Department of Health and Human Services (DHHS) Office for
Human Research Protections, and three universities where Dr. New has held or holds appointments. We
provide a critical appraisal of the Letter of Concern and show that it makes false claims, misrepresents
scientific publications and websites, fails to meet standards of evidence-based reasoning, makes
undocumented claims, treats as settled matters what are, instead, ongoing controversies, offers “mere
opinion” as a substitute for argument, and makes contradictory claims. The Letter of Concern is a case
study in unethical transgressive bioethics. We call on fetaldex.org to withdraw the letter and for cosignatories to withdraw their approval of it.
Keywords: bioethics, fetal treatment, human subjects research, methodological integrity, off-label use
of medications, public advocacy, transgressive bioethics

On February 3, 2010, a “Letter of Concern from Bioethicists” was sent to report
suspected violations of the ethics of human subjects research in the off-label use (i.e.,
not for purposes approved by FDA) of dexamethasone (a glucocorticoid steroid)
during pregnancy “for the purposes [sic] of preventing genital virilization associated
with CAH[congenital adrenal hyperplasia] in 46,XX females,” by Dr. Maria New,
Professor of Pediatrics at Mount SinaiMedical Center in New York City (fetaldex.org
2010a; Appendix). The effort was organized by fetaldex.org, which continues to
update this “action:” “We have organized a group of professional researchers in
bioethics and allied fields to file formal letters of concern” (fetaldex.org 2010b).
Copies of this letter were submitted to the U.S. Food and Drug Administration (FDA)

Office of Pediatric Therapeutics, the U.S. Department of Health and Human Services
(DHHS) Office for Human Research Protections, Mount Sinai Medical Center, Weill
Medical College of Cornell University (“from which much of this treatment appears to
have been administered, under Dr. New’s guidance” when she served on Cornell’s
faculty), and Florida International University (“where Dr. New is Associate Dean for
Clinical Research”).
The stated purpose of fetaldex.org, which was founded in 2010, is the
following:
This website seeks to raise awareness regarding the
prenatal use of dexamethasone, a Class Csteroid, to
attempt to prevent a female fetus from developing genitals
that are more in-between a male and female type.
(fetaldex.org 2010b)
Ellen Feder, Ph.D., of American University, appears as corresponding author,
followed by 31 co-signatories and three “additional supporters of inquiry (offered to
sign after letters had already gone in).”
The “Letter of Concern from Bioethicists” (hereinafter referred to as LoC) and
the subsequent activities of fetaldex. org can usefully be characterized as an exampleof
transgressive bioethics. Transgressive bioethics combines attention-getting tropes with
traditional philosophical argument to challenge accepted clinical practice or research
in a deliberately provocative fashion, to expose what is taken to be unethical practice
and reform it. Transgressive bioethics can be understood as aiming to fulfill a
traditional role of the humanities: to speak truth to power in a conspicuous fashion, to
bring power to account. There is nothing intrinsically objectionable to transgressive
bioethics, when it meets the intellectual and moral standards required to produce a
public discourse of bioethics that is “reasonable” (Jonsen 1998, 353). The purpose of
this paper is to show that the “Letter of Concern from Bioethicists” and the subsequent
activities of fetaldex.org fail to meet these intellectual and moral standards, making
this episode a case study in unethical transgressive bioethics.
DR. NEW’S RESEARCH
The target of the LoC is the research of Dr. New. The first requirement of
sound bioethics, including transgressive bioethics, is reproducing empirically
verifiable facts completely and accurately (De Grazia and Beauchamp 2001). We
therefore start with an account of Dr. New’s research on prenatal use of
dexamethasone to prevent virilization of the female fetus affected by congenital
adrenal hyperplasia (CAH). CAH is a genetic hormonal disorder resulting in anatomic
and physiologic masculinization of females.
Dr. New is one of the leading pediatric endocrinologists in the world, having
made many contributions to our understanding and treatment of adrenal disorders.
Many scholars have written about the most frequent adrenal disorder, i.e., CAH owing
to 21-hydroxylase deficiency (21OHD). Indeed, the first anatomical description was

reported De Chrecchio (1865) in Italy. Grunberger and Boschitsch (1981) reported the
case histories of 22 adult female patients aged 15 to 27 years before any prenatal
therapeutic program had been developed. All treatment was at that time postnatal.
Because of genital masculinization and, in the majority of cases, despite some form of
corrective genital surgery (mostly clitorectomy), 11 of the women could not engage in
heterosexual intercourse. Menarche occurred spontaneously in only 10 cases. Because
prenatal testing was not yet available, the diagnosis was made postpartum, at which
time the treatment of choice was the administration of a corticosteroid. From the
standpoint of ameliorating genital ambiguity (but one conspicuous effect of high levels
of intrauterine androgen exposure), intervention at this stage is considerably less than
efficacious.
With the advent of prenatal diagnosis of CAH through chorionic villus
sampling or amniocentesis (depending on when the pregnant woman first presents for
obstetric care) came the opportunity for earlier therapeutic intervention in pregnant
women at high risk for carrying a child with CAH. The pioneer in prenatal treatment
to prevent genital ambiguity was Maguelone Forest in Lyon, France, who reported the
first prenatal treatment of CAH in 1987 (Forest, B´etuel, and David 1987). In 1986 Dr.
New utilized Dr. Forest’s protocol to initiate prenatal diagnosis and treatment in the
United States (New 1990; Karaviti et al. 1992). Many other countries have now begun
a program of prenatal diagnosis and treatment of CAH to prevent genital ambiguity.
The protocol is as follows.
An obstetrician who performs chorionic villus sampling or amniocentesis
requests prenatal diagnosis by sending a sample of tissue to Dr. New. The pregnant
woman’s obstetrician makes a referral to Dr. New for the purpose of tissue analysis for
21OHD. DNA is sent to Dr. New’s laboratory for analysis. She often requires DNA
from the father as well, unless it was obtained from a previous pregnancy consultation.
The pregnant woman has requested prenatal diagnosis and treatment because
she has a member of her family who is affected with 21OHD and therefore the fetus is
at risk. Prenatal treatment with dexamethasone for 21OHD must be initiated before the
9th week of gestation to be effective, because sexual differentiation of genitalia
typically occurs between the 9th and 13th week of gestation and chorionic villus
sampling or amniocentesis cannot safely be performed prior to this milestone. Once
the presence of normal 21OHD is identified and/or the fetus is identified as male,
dexamethasone therapy is discontinued. Male fetuses and unaffected female fetuses do
not require prenatal treatment, but neither the referring physician nor Dr. New knows
this until the genetic diagnosis is made. Therefore, treatment is initiated by the
referring obstetrician blind until the status of the fetus is determined (male or female,
affected or unaffected).
DNA diagnosis takes about 2–3 weeks, depending on whether the cells grow
well enough. The dose of dexamethasone is 20 µg per kilogram per day in three
divided doses, based on prepregnancy weight, with a maximum dose of 1.5 mg of
dexamethasone per day. When the genetic information becomes available, Dr. New’s
office immediately calls the referring obstetrician to report whether the fetus is a male
or unaffected female and advises the doctor to stop the treatment. If it is a female that

is affected genetically, the woman is administered dexamethasone until term. Dr. New
asks for a postnatal follow-up to be sure that the prenatal diagnosis is correct. Followup data are gathered by Dr. New under an institutional review board (IRB)-approved
protocol with informed consent for data collection, analysis, and reporting (Trautman
et al. 1995; New et al. 2001).
The short-term outcome of preventing genital ambiguity in the affected female
is 100% effective, providing that the pregnant woman is compliant and the
dexamethasone is administered properly. The referring obstetrician obtains consent
and writes the prescription for dexamethasone. Frequently, Dr. New must provide
advice as to the dose and the duration. It is of note that Dr New herself has written the
prescription for dexamethasone for only one patient: a pregnant woman who is herself
a patient with a severe form of CAH who became pregnant with a female fetus who
was also affected with a severe form of CAH (personal communication with Dr. New).
Dexamethasone is administered at a very low dose (20 µg/kg/day of
prepregnancy weight in 3 divided doses). At this low dose, dexamethasone does not
have teratogenic potential, and furthermore, because the therapy does not begin until
just before the ninth week of gestation, organogenesis of the major organs has been
completed, so on both counts a risk for induced birth defects is not present.
To date more than 800 fetuses have been diagnosed by genetic analysis of fetal
tissue worldwide, so that in many countries, including the United States, prenatal
diagnosis and treatment has become the standard of medical care. It should also be
pointed out that the regulatory agencies in some countries have approved this protocol.
This status of prenatal use of dexamethasone as standard of care is reflected in the
major obstetrics textbooks. Danforth’s Obstetrics is illustrative:
Approximately 90% of patients with CAH during
pregnancy have a partial or complete deficiency of the
21-hydroxylase enzyme. The resultant decrease in
cortisol production leads to increased ACTH stimulation,
which then results in both increased production of
androgenic cortisol precursors . . . and decreased
production of aldosterone. Because these androgenic
steroids readily cross the placenta, pregnancies
complicated by significant maternal 21-hydroxylase
deficiency are at increased risk for fetal virilization.
Such virilization is most apparent in female infants,
although male infants also may have somewhat enlarged
external genitalia. The risk of fetal virilization is reduced
if pregnant patients with CAH receive adequate basal
glucocorticoid replacement together with additional
glucocorticoid in times of stress. Mineralocorticoid
replacement should be continued as well. (Krakow 2008)
DR. NEW HAS “LONG PRESCRIBED” PRENATAL EXAMETHASONE:A
FALSE CLAIM

The LoC states in its second paragraph:
It is our understanding that Dr. New has long prescribed
dexamethasone for purposes of preventing genital
virilization associated with CAH in 46,XX females.
Dr. New has prescribed dexamethasone prenatally in only one case, as we
documented earlier. This central factual claim of the LoC is therefore false. That it
could be advanced reflects the failure to undertake the research required to document
this claim. Had such research been undertaken, the claim could not have been
truthfully made. Making false claims as a consequence of the failure to meet the
standard of reproducing empirically verifiable facts completely and accurately (De
Grazia and Beauchamp 2001) is intellectually irresponsible and therefore unethical
transgressive bioethics. By itself, this false claim discredits the LoC. However, there
are multiple additional flaws in it that betray its systematically unethical nature. We
address each in turn.
PRENATAL ADMINISTRATION FOR DEXAMETHASONE IS COSMETIC:
FALSE REPRESENTATION OF THE POSITION OF A SCIENTIST
The second paragraph of LoC states:
Genital virilization is a cosmetic issue, one that has been
recognized within Dr. New’s field as independent of the
genuine medical concerns—often serious and lifethreatening in some forms of CAH—unaddressed by
prenatal dexamethasone treatment. That is to say, prenatal
treatment with dexamethasone is intended to avoid a
cosmetic issue associated with CAH, rather than to treat
the medical issues that should be the primary concern of
physicians. (emphasis original)
No argument is made to support the clinical ethical judgment that genital
virilization of females is a “cosmetic issue.” Instead, reference is made to a paper by
Walter Miller (1999), a pediatric endocrinologist.
Miller reports the complications of virilization as “persistence of a urogenital
sinus, labioscrotal fusion and clitoromegaly, which are surgically correctable. This
fetal hyperandrogenism may alsomasculinize the brains of affected females” (Miller
1999, 537). The LoC mentions only one of these complications, clitoromegaly,
without explanation.
Miller reports on the use of prenatal dexamethasone, “There is now sufficient
clinical experience so that present dexamethasone protocols result in little or no
masculinization of the female genitalia” (Miller 1999, 537), and cites work by Dr.
New in support. Miller goes on to make the case that prenatal use of amethasone is
“experimental.” He points out that unaffected fetuses “will receive at least 6 weeks of

dexamethasone treatment before a diagnosis is made” (Miller 1999, 537); that “only 1
in 8 pregnancies to a couple with a previously affected child has a theoretical chance
to be helped by prenatal therapy” (Miller 1999, 538); that the dosages exceed normal
fetal glucocorticoid levels by a factor of 10; that the mechanism by which virilization
may be altered is not well understood; and that “the teratogenic effect of
dexamethasone has not been evaluated definitively” (Miller 1999, 538).Miller
emphasizes the point that the long-term risks are not well understood as “most
difficult” (Miller 1999, 538). He concludes:
The genitalia of virilized females can be repaired
surgically but adrenogenization of the brain is irreversible;
hence, prenatal dexamethasone treatment may offer unique
advantages. However, the ethics of needlessly subjecting 7
of 8 fetuses to an experimental therapy with unknown
long-term consequences remain unresolved because the
long-term safety and outcome have not been established.
Therefore, prenatal treatment of CAH remains
experimental. (Miller 199, 538)
Miller goes on to call for the administration of prenatal dexamethasone under
protocols limited to “large centers that receive a large enough number of patients to
yield meaningful research results” (Miller 1999, 538–539). Miller also sets out the
domains of information that should be included in the informed consent process for
such research.
Nowhere in his article does Miller use the word “cosmetic” or any of its
cognates. The reference to the Miller paper in the LoC to support its claim that
prenatal administration of dexamethasone is cosmetic is erroneous because it is
inconsistent with the plain language of the Miller paper. Miller, as just quoted,
characterizes virilized genitalia as surgically reparable but makes no mention that this
is a cosmetic procedure. Instead, he treats such surgery as a medical issue “that should
be of the primary concern of physicians,” to use the language of the LoC. Worse,
Miller directly supports the opposite view when he acknowledges that virilization of
the brain is an “irreversible” complication and thus of clinical significance. In
summary, the LoC falsely represents Miller’s paper as stating that prenatal
administration of dexamethasone is merely cosmetic.
SUBSEQUENT ADMISSION THAT PRENATAL ADMINISTRATION
OF DEXAMETHASONE IS NOT COSMETIC
Hilde Lindemann, Ph.D., of Michigan State University, joined Drs. Feder and Dreger
in a posting on the bioethics blog site of The Hastings Center, reiterating the claims
advanced in the LoC (Lindemann, Feder, and Dreger 2010a). One response was from
an interdisciplinary group from Harvard Medical School (Diamond et al. 2010). David
Diamondand colleagues pointed out that virilization of females with CAH in its severe
forms includes a persistent urogenital sinus, an anomaly in which the urethra and
vagina form a single channel. They write: “Even without doing surgery on the
enlarged clitoris, surgical reconstruction to separate the urinary and reproductive tracts

in childhood is necessary to prevent urinary incontinence and infections leading to
renal damage as well as to allow normal urination and future sexual function”
(Diamond et al. 2010). Diamond and colleagues also point out that Miller
underestimates the complications of neonatal surgery to correct this problem.
Prevention of this anatomic anomaly, they correctly add, is not cosmetic.
Drs. Lindemann, Feder, and Dreger responded as follows:
The reason we did not pay enough attention to this point is
explained by our focus on New’s work on prenatal
dex[amethsasone], which appears after much review to
stand out as atypical. In her promotion of prenatal dex to
“at risk” women, New emphasizes the prevention of
ambiguous genitalia as the most important aim of
intervention. This has implied that ambiguous genitalia
represent some kind ofmedical problem in and of
themselves.
Obviously it would be good if medically necessary
interventions (for example, surgery to correct a severe
urogenital sinus) could be made unnecessary through
prevention, as some interventions for neural tube defects
have been prevented through increasing fertile women’s
intake of folic acid. That said, we remain extremely
concerned about the way that prenatal dex is being
promoted and administered, and we do not see the
potential for a postnatal urogenital sinus as a license to do
what has been done. (Lindemann, Feder, and Dreger
2010b)
This response amounts to an admission that the attenuation of virilization with
dexamethasone prevents more than just clitoromegaly; it also prevents clinically
significant anatomic anomalies and therefore prevents “medically necessary
interventions,” not just cosmetic procedures. As a result, they contradict and thus
nullify one of the central claims in the LoC, that prenatal administration of
dexamethasone for affected female fetuses is merely cosmetic.
MISREPRESENTATION OF CARES FOUNDATION WEBSITE
The LoC cites a CARES (Congenital Adrenal Hyperplasia Research Education &
Support) Foundation document twice. The website is described as “online promotion
of the treatment of dexamethasone administered by Dr.New’s clinic.”
The CARES Foundation was incorporated in 2001 as a 501(3)(c) nonprofit
organization (CARES Foundation 2009). It is not associated with Dr. New’s clinic, as
the LoC implies in its ambiguous wording. This website is also cited in the LoC to
support its claim that Dr. New has recruited pregnant women “without the benefit of

IRB oversight.” The website makes no such claim. The CARES website is thus
misrepresented twice.
PRENATAL ADMINISTRATION OF DEXAMETHASONE
HAS SIGNIFICANT IATROGENIC RISK: FAILURE TO
MEET THE STANDARDS OF EVIDENCE-BASED REASONING
The LoC makes two related claims about the risk of prenatal administration of
dexamethasone. The LoC concludes its second paragraph with: “Furthermore, use of
prenatal dexamethasone has been demonstrated to bear significant iatrogenic risk.”
The LoC concludes its fifth paragraph with: “contrary to the apparent claims aimed at
prospective patients, dexamethasone treatment cannot responsibly be characterized as
benign.”
Claims about the clinical benefits and risks of any clinical intervention should
be evidence based. Bioethics is held to this exacting intellectual standard no less than
clinical practice and research (Sulmasy and Sugarman 2001). The accepted standard
for establishing unacceptable risk of a clinical intervention is a systematic review of
the literature. No such review is described in the LoC. Instead, five papers are cited
and no search strategy is described, in a letter being sent to federal agencies committed
to evidence-based advancement of biomedical science and clinical practice. The LoC
has an intellectual obligation to rebut Dr. New’s work by appealing to an evidencebased analysis of her work in the context of the results of a systematic review. That
theLoC fails to meet the fundamental standard of evidence-based reasoning is a
fundamental error.
The LoC asserts that perinatal treatment with dexamethasone puts fetuses at
risk for neurotoxicity. The LoC references a study performed on 8 rhesusmonkeys (3
of which were given placebo) thatwere administered dexamethasone in doses of 5
mg/kg (Uno et al. 1994). For reference, the typical dose given to pregnant (human)
women was 20 µg/kg. The LoC provides no justification for its extrapolation from the
results of a study of 5 rhesus monkeys that were administered a single, 200-fold higher
dose of dexamethasone than that administered to human female fetuses affected by
CAH.
In support of its claim about “significant iatrogenic risk” the LoC cites a 2000
NIH Consensus Development Conference Statement (National Institutes of Health
Consensus Development Panel 2001). The LoC neglects to mention that this is a
statement on the use of antenatal steroids to promote fetal maturation, a clinical entity
very dissimilar fromCAH. The NIH statement does not address prenatal administration
of dexamethasone to prevent the clinical complications of CAH. Prenatal use of
steroids to promote fetal maturity occurs later in gestation and at a much higher dose.
This fundamental clinical disanalogy to prenatal use of dexamethasone for prevention
of virilization is not acknowledged, much less addressed in the LoC.
Even if the NIH statement were clinically relevant, the statement does not
support the claim of the LoC. This is because the LoC omits the conclusion of this
statement, which reads: “The collective international data continue to support

unequivocally the use and efficacy of a single course of antenatal corticosteroids using
the dosage and interval of administration specified in the 1994 Consensus
Development Conference report” (National Institutes of Health Consensus
Development Panel 2001, 144, emphasis added).
The fetaldex.org website refers to a summary (“Cognitive functions” 2009)
that appeared in Growth, Genetics, and Hormones about a study to “show that this
prenatal dex treatment may result in detrimental changes to the brains of children
given the drug in the womb.” The “About the Journal” webpage for this publication
(http://www.gghjournal.com/atAGlance.cfm, accessed April 22, 2010) does not
describe this journal as peer reviewed. It is not listed in the Web of Knowledge journal
citation reports and therefore has no impact factor. The fetaldex. org Web site does not
report any of this information and does not report that it relies on a summary of an
article cited in the LoC (Hirvikoski et al. 2007).
The fetaldex.org website does not portray the summary accurately. It states that
there was no statistically significant difference reported for such cognitive functions as
verbal comprehension and IQ but that there were statistically significant differences
for memory function. The accompanying “Editor’s Comment” to this study suggests
several more problems: “the sample size is small limiting statistical power; the
assessment of school performance was self-reported and based on a measure of limited
utility in detecting subtle learning problems; the generalizability of the findings are
limited to children younger than 18 years, i.e., the pattern of neurocognitive effects
may depend on chronologic age” (Sandberg 2009). Furthermore, in the study in
question, the control-group children in the study were CAH-unaffected. That is, this
study did not actually have a control arm of patients not altered by dexamethasone
therapy, so that the null hypothesis of the study fails to be invalidated by virtue of a
key methodological flaw of the study. These crucial methodological limitations are left
unmentioned on the fetaldex.org website and in the LoC.
The LoC also cites a study (French et al. 2004) to support its claim that that
prenatal administration of dexamethasone “results in detrimental changes to the brains
of children.” The population studied was children whose mothers had been
administered steroids for preterm births, not CAH-affected females. As in the case of
its reference to the NIH Consensus Panel, analyzed earlier in this article, the LoC does
not report this difference in populations, with the same disabling problems for the
LoC. Worse, the paper reports a protective effect of fetal dexamethasone against
cerebral palsy and an association with hyperactivity in children treated. These mixed
results are not reported in the LoC and do not support its unequivocal claim about
brain changes.
Finally, the usual evidence-based approach to judging the efficacy of an
intervention in a population is based on the number needed to treat (NNT) and the
number needed to harm (NNH). The NNT for prenatal dexamethasone administration
is 8 (the number of fetuses exposed before genetic analysis is completed and one
affected fetus is identified). Contrast this to the NNT for childhood influenza
vaccination to prevent one hospitalization per year: between 1031 and 3050 for
children 6–23 months and between 4255 and 6897 for children 24–59 months of age

(Lewis et al. 2007). The NNH for prenatal dexamethasone would have to be calculated
on the basis of a systematic review of the literature that described statistically
significant differences in harms between CAH-affected children who were prenatally
treated with dexamethasone and CAH-affected children who were not. The peerreviewed papers cited in support of the LoC’s claim about “significant iatrogenic risk”
are either human studies without the required control group or animal studies.
Therefore, the NNH for prenatal dexamethasone for affected female fetuses cannot be
calculated on the basis of the references in the LoC. The claim of the LoC that
“prenatal dexamethasone has been demonstrated to bear significant iatrogenic risk”
lacks empirical foundation and therefore violates the standards of evidence-based
reasoning.
Were the authors of the LoC more charitably attuned to the substance of Dr.
New’s research, they would have found a number of studies over the years that
examined, in great detail, concerns regarding neurotoxicity and all manner of other
forms of potential teratogenicity. It turns out that Dr. New has pondered and studied
the concerns regarding antenatal neurotoxicity in humans in publications going back to
1995 (Trautman et al. 1995) and she continues to study the hypothesis today. In one
2004 study (Meyer-Bahlberg et al. 2004), New and colleagues examined 174 children,
newborn to age 12 years, who were exposed to dexamethasone perinatally, of which
48 had CAH. These children were compared to 313 unexposed children, including 195
with CAH. New and colleagues used four different developmental questionnaires
chosen for age-appropriateness and found that exposure to dexamethasone
demonstrated no statistically significant correlations between dexamethsone
administration and developmental delay on any measure, in any of the groups. Dr.
New has also authored studies demonstrating that dexamethasone-treated fetuses had
no difference in birth weight, length, and head circumference and that the risk of fetal
loss was not higher than the general population (New et al. 2001). Given the low
prevalence of CAH, this is likely to be among the largest study populations ever
available for this disease.
By contrast, the PREDEX study relied upon by the LoC has been enrolling
patients prospectively in several European countries since 1999, and had only reported
enrolling 14 patients through 2004 (Lajic 2004). The lead investigator for PREDEX,
Dr. Svetlana Lajic, has published several studies on the neurocognitive effects of
perinatal administration of dexamethasone over several years (Lajic 2004; Hirvikoski
2007; 2008). One study (Hirvikoski 2007) reported lower rates of verbal working
memory and higher rates of social anxiety in CAH-unaffected patients treated with
dexamethasone (n = 26), though this same index was measured and not identified as
statistically significant by New and colleagues (n = 174). In a follow-up study,
Hirvikoski and colleagues report that their previous findings were not able to be
reproduced, and may have been the result of a Type I error due to small sample size
(Hirvikoski, 2008), lending credence to the results of studying a larger sample size
such as reported by New and colleagues. Regardless, the data cited by the authors of
the LoC do not support the LoC’s claim that “dexamethasone treatment cannot
responsibly be characterized as benign.” Indeed, the preponderance of evidence
suggests that the therapy is benign.

It is a perennial challenge to study the long-term effects of a therapy for a
condition that has a low incidence and prevalence, particularly when the effects being
studied (neurocognitive behaviors) are affected by a vast array of factors. It is
therefore all the more impressive that a dispassionate review of the empirical literature
on the subject finds that Dr. New’s work represents the most methodologically sound
and statistically convincing evidence that significant adverse neurocognitive outcomes
attributable to perinatal dexamethasone therapy have yet to be convincingly reported.
Assertions to the contrary have no basis in the empirical literature on the subject.
OFF-LABEL ADMINISTRATION OF DEXAMETHASONE IS RESEARCH
THAT SHOULD BE CONDUCTED ONLY WITH IRB OVERSIGHT: AN
APPEAL TO A NONEXISTENT ETHICAL STANDARD
The third paragraph of the LoC states:
Off-label use of prescription medication is a long-time
practice of medicine that has not been understood to
constitute research requiring IRB oversight. We do not
take issue here with the practice of off-label prescribing in
general. We are concerned instead with a particular
instance of what appears to constitute a de facto clinical
trial involving many hundreds of patients now among the
targeted “subjects” of long-term research. In clear
violation of established bioethical protocols, these
pregnant women appear to have been recruited (and
perhaps are still being recruited) without the benefit of
IRB oversight.
The last sentence has a reference to the CARES website about Dr. New’s
research, which we addressed earlier.
Two claims are made in this paragraph of the LoC. The first is that off-label
use of prenatal dexamethasone “appears to constitute a de facto clinical trial.” The
second is that Dr. New is conducting follow-up studies of the long-term outcomes of
prenatal dexamethasone without IRB approval. The latter claim is demonstrably false,
as is clear from the plain language in Dr. New’s 2001 report on the follow-up, which
states: “The study was approved by our institution’s review board for human rights in
research. Informed consent was obtained from mothers” (New et al. 2001, 5654; see
also Trautman et al. 1995, which is cited in the LoC).
The claim that prenatal use of dexamethasone is a “defacto clinical trial” is
neither clarified nor justified by the LoC. Assertion made without supporting
argument, as Plato had Socrates teach us long ago, constitutes “mere opinion.” “Mere
opinions” are not valid argument forms, because they are conclusions in search of
premises.
To determine whether supporting premises might be available, we performed a
literature search in PUBMED using “off label use AND ethics” that yielded 68

citations (April 22, 2010). The oldest citation is from 1994. The absence of a literature
on the topic means that there was no ethical analysis and argument, much less a
consensus ethical standard, that off-label use of prescription medications is research.
Thus, no ethical standard for off-label use of drugs existed when Dr. New began her
treatment protocol in 1986. The LoC falsely assumes such a standard has always
existed. To avoid this criticism, the LoC could have cited a consensus ethical
standard. The LoC does not do so
because, as our review of the 68 citations indicates, there is no such standard in the
literature. Grant, for the sake of argument, that such a standard has just been created.
To apply it to clinical practice from 25 years ago commits the terror of presentism, i.e.,
applying ethical standards of the present as if they applied throughout human history,
against which historians rightly warn us (Pernick 2009). The claim that prenatal
administration of dexamethasone constitutes a “de facto clinical trial” fails.
UNDOCUMENTED CLAIM THAT PREGNANT WOMEN MAY NOT HAVE
PROVIDED INFORMED CONSENT FOR ADMINISTRATION OF
DEXAMETHASONE
The sixth paragraph of the LoC states:
It does not appear that physicians prescribing this drug to
hundreds of women have sought IRB approval for clinical
trials of dexamethasone for the purposes of minimizing
virilization [and that therefore] pregnant women who have
been prescribed dexamethasone external to IRB-approved
trials may not have provided fully informed consent as
would happen formally under an IRB-approved trial.
The LoC assumes that obstetricians prescribing dexamethasone in such cases
would not adhere to ethical and legal standards of informed consent in clinical
practice, simply because there was no IRB oversight. This is a non sequitur. Moreover,
it calls into question the professional integrity of scores of physicians without a shred
of evidence being offered for the plausibility of the hypothesis of systematic and
widespread violation of the ethical and legal standards of informed consent in obstetric
practice for the prenatal administration of dexamethasone.
A CALL FOR CLINICAL TRIALS: AN UNORIGINAL CLAIM THAT LACKS
SUPPORTING ARGUMENT
The LoC states in its seventh paragraph:
Given the well-established risks to fetal development,
physicians should initiate treatment of this type only
through structured clinical trials with human subjects
research protections in place.
This call for clinical trials under IRB oversight is not based on the earlier claim
that off-label use of prenatal dexamethasone is by definition experimental, which we

addressed earlier. It is, instead, the claim that, because the long-term outcomes of
prenatal administration dexamethasone are not known and because some risks have
been reported, prenatal dexamethasone should be offered only under a clinical
protocol. To be sure, the authors of the LoC trade heavily on the existence of
uncertainty as regards the risks of dexamethasone, but the mere existence of
disagreement does not speak to the merits of whether there is empiricalsupport for
disagreement about the risks of dexamethasone.We have suggested that much of this
uncertainty is predicated on studies that either are not germane to the specific question
regarding the administration of dexamethasonein this setting or are predicated on
small clinical studies that are statistically underpowered compared to the data reported
by Dr. New and in which tentative observations of potential harm are not reproduced
in subsequent studies. The authors may have gleaned their argument from Miller
(1999) in his 1999 paper cited by the LoC, but the Miller paper is not cited in this part
of the LoC. Perhaps this is becauseMiller offers nomore empirically substantive
basisfor his claims than the authors of the LoC proffer.
The LoC statement is not consistent with the 2002 consensus statement from
the Lawson Wilkins Pediatric Endocrine Society and the European Society for
Paediatric Endocrinology, which the LoC does not cite. This statement reads: “There
is substantial difference of opinion concerning whether prenatal treatment of CAH is a
research endeavor” (Joint LWPES/ESPE CAHWorking Group 2002, 4049). No
position is taken on the matter, a fact that the LoC fails to report.
In bioethics when one asserts a position that is controversial, one is obligated
as a matter of intellectual integrity to advance an argument for one’s position (De
Grazia and Beauchamp 2001). The LoC offers as the single premise: “Given the well
established risks to fetal development.” As we pointed out earlier, in the absence of a
structured scientific review of the literature and an analysis of the NNT and NNH
based on such a review, the use of “well established” lacks empirical justification.
Grant, however, that it is a reasonable claim. This “premise” reflects an incomplete
ethical analysis, because there is no comprehensive analysis of the outcomes. For the
premise to reflect an adequate ethical analysis, one would have to show that, on
balance, the well established risks are not offset by clinical benefits, especially the
amelioration of virilization. The consensus statement from the Joint LWPES/ESPE
CAH Working Group states that it is “clear” that such ameliorization is accomplished,
a conclusion that we believe is readily sustained by an assessment of the totality of the
literature, including the body of clinical studies published by Dr. New. The claim that
there should be clinical trials lacks supporting argument.
CLINICAL TRIALS SHOULD NOT BE PURSUED: A CLAIM THAT
CONTRADICTS THE CALL FOR CLINICAL RESEARCH
In the final paragraph of the LoC, which comes immediately after the paragraph in
which the call for clinical trials is made, the LoC states:
Finally, we agree with Dr.Walter Miller, Distinguished
Professor of Pediatrics and Chief of Endocrinology at the
University of California San Francisco, who has written

that “this experimental treatment is not warranted and
should not be pursued even in prospective clinical trials.”
The quoted passage is from a recent column by Miller in EndocrineNews
(Speiser and Miller 2008). In it, he provides a condensed version of the argument that
he made in his 1999 paper, cited in the LoC and discussed earlier. Miller concludes his
EndocrineNews column with: “It is this author’s opinion that this experimental
treatment is not warranted and should not be pursued, even in prospective clinical
trials” (Speiser and Miller 2008, 17). Miller provides no argument for his opinion,
which is required to justify the rejection of his earlier call for clinical trials (Miller
1999). In endorsing Miller’s opinion that clinical trials should not be undertaken the
LoC contradicts its call, issued in the preceding paragraph, for clinical trials to be
undertaken. The LoC thus violates the law of noncontradiction, the most fundamental
requirement of argument-based reasoning.
MAJOR DIFFERENCES BETWEEN VERSION CIRCULATED TO SOLICIT
CO-SIGNATORIES AND SUBMITTED VERSION
The original version circulated to solicit individuals to become co-signatories
contained no references. Major changes were made after co-signatories added their
names to the draft LoC. There was no indication that changes would subsequently be
made after the agreement of co-signatories to add their names.
In an exchange on the bioethics listserv sponsored by the Medical College of
Wisconsin, two of us (FAC and LBM) pointed out that numerous claims were made
without substantiation in what turned out to be a draft version of the LoC. The initial
response of the authors was that the LoC was not a scholarly paper and therefore was
somehow exempt from accepted standards of scholarship. Such a position would
disable transgressive bioethics. References were added in the submitted version. We
addressed earlier the inadequacy, misuse, and false representation of the references.
This substandard scholarship disables the LoC as transgressive bioethics that meets
minimal standards of intellectual rigor and integrity.
The opening sentence of the circulated unreferenced draft reads: “We write to
express our grave concern that a research group affiliated with your institution may be
engaging in an unapproved, off-label pharmaceutical trial targeted at pregnant women
and their fetuses.” This sentence does not appear in the submitted version. The sixth
paragraph of the submitted LoC concludes with: “Public descriptions of this drug as
safe and effective may have misled some women to believe the use is FDA-approved,
when it is not.” This sentence does not appear in the draft circulated to solicit cosignatories. The final paragraph of this version of the LoC starts with: “We call for
rigorous investigation by your institution into whether researchers associated with
your institution are currently or have previously treated pregnant women with
dexamethasone to prevent genital virilization.” The final paragraph of the submitted
LoC begins with: “We call for rigorous investigation by the FDA into possible
regulatory violations in this matter.”

There is no indication in the submitted LoC that the cosignatories were made
aware of these major changes in the LoC. There is also no indication that the cosignatories read and approved the submitted version of the LoC.
CONCLUSION
Rebecca Dresser and Joel Frader (2009) recently called for “responsible selfregulation” of off-label use of drugs. This has been a common practice not only in
obstetrics but also in pediatrics and adult medicine and surgery in general for decades.
Specifically, there is ongoing discussion in the scientific community on whether the
prenatal administration of dexamethasone to prevent the complications of CAH in
affected females is experimental or standard of care (Joint LWPES/ESPE CAH
Working Group 2002).
The LoC could have contributed to this important topic. Instead, the LoC
makes false claims; misrepresents scientific publications and websites; fails to meet
the fundamental standards of evidence-based reasoning; makes undocumented claims;
treats as settled matters what are, instead, ongoing controversies; offers “mere
opinion” as a substitute for argument; and makes contradictory claims. The LoC is
therefore a case study in unethical transgressive bioethics.
We call on fetaldex.org as the self-proclaimed organizer of “a group of
professional researchers in bioethics and allied fields to file formal letters of concern”
(fetaldex.org 2010b), and the corresponding author to withdraw the LoC from the
government agencies and academic institutions to which it was submitted and to
announce the withdrawal publicly on its website and the bioethics listerv. We also call
on the co-signatories to remove their names from the LoC, to report their decision to
remove their names to the government agencies and academic institutions to which the
LoC was sent, and to inform fetaldex.org of their decision. We call on fetaldex.org to
post notices of withdrawal by co-signatories from the LoC on its website.
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APPENDIX: fetaldex.org LETTER OF CONCERN FROM BIOETHICISTS
The following letter has been sent to:
1. the FDA Office of Pediatric Therapeutics;
2. the HHS Office for Human Research Protections;
3. Mount Sinai Medical Center (Dr. New’s current institution);
4. Weill Medical School of Cornell University (from which much of this treatment
appears to have been administered, under Dr. New’s guidance);
5. Florida International University (where Dr. New is Associate Dean for Clinical
Research).
The preliminary FDA response is shown here; the Office of Human Research
Protections preliminary response is shown here.
Dear Sir or Madam:
We write to express our grave concern over possible non-IRB-approved
clinical research on pregnant women that has been conducted under the auspices of
Mount Sinai Medical Center and Weill Cornell Medical College, Cornell University,
under the direction of Dr. Maria New.

This work involves off-label administration of dexamethasone to pregnant
women who may give birth to girls with Congenital Adrenal Hyperplasia (CAH). It is
our understanding that Dr. New has long prescribed dexamethasone for purposes of
preventing genital virilization associated with CAH in 46,XX females. This indication
is not approved by the FDA. Genital virilization is a cosmetic issue, one that has been
recognized within Dr. New’s field as independent of the genuine medical concerns—
often serious and life-threatening in some forms of CAH—unaddressed by prenatal
dexamethasone treatment. That is to say, prenatal treatment with dexamethasone is
intended to avoid a cosmetic issue associated with CAH, rather than to treat the
medical issues that should be the primary concern of physicians.[1] Furthermore, use
of prenatal dexamethasone has been demonstrated to bear significant iatrogenic
risk.[2]
Off-label use of prescription medication is a long-time practice of medicine
that has not been understood to constitute research requiring IRB oversight. We do not
take issue here with the practice of off-label prescribing in general. We are concerned
instead with a particular instance of what appears to constitute a de facto clinical trial
involving many hundreds of patients now among the targeted “subjects” of long-term
research. In clear violation of established bioethical protocols, these pregnant women
appear to have been recruited (and perhaps are still being recruited) without the benefit
of IRB oversight.[3]
In professional contexts among her peers, Dr. New has publicly resisted
discussion of the details of the information pregnant women and their partners are
provided. One online promotion of the treatment with dexamethasone administered by
Dr. New’s clinic nevertheless promised that follow-up with hundreds of children
treated prenatally over 20 years “has found no adverse developmental consequences. .
..the treatment appears to be safe for mother and child.”[4]
Human studies have demonstrated, on the contrary, that prenatal
dexamethasone treatment results in detrimental changes to the brains of children,[5]
over 90% of whom will receive no benefit from this treatment. (Only 1 in 8 fetuses
started on this treatment are actually 46,XX CAH, and of the 1/8 who are, 20% will
not benefit from the treatment.) Children exposed prenatally to dexamethasone for
CAH show problems with working memory, verbal processing, and anxiety.[6]
Animal studies have also indicated reason to be very concerned about prenatal
dexamethasone’s effect on fetal brains.[7] Therefore, contrary to the apparent claims
aimed at prospective patients, dexamethasone treatment cannot responsibly be
characterized as benign.[8]
Despite knowledge of risks to fetal development, it does not appear that
physicians prescribing this drug to hundreds of women have sought IRB approval for
clinical trials of dexamethasone for the purposes of minimizing genital virilization in
46,XX females at risk for CAH in utero. Pregnant women who have been prescribed
dexamethasone external to IRB-approved trials may not have provided fully informed
consent as would happen formally under an IRB approved trial. Public descriptions of

this drug as safe and effective may have misled some women to believe the use is
FDA-approved, when it is not.
Given the well-established risks to fetal development, physicians should
initiate treatment of this type only through structured clinical trials with human
subjects research protections in place. Registered clinical trials ensure that women and
their families make fully informed decisions with respect to the risks they assume for
themselves and on behalf of their future children. Studies such as these also ensure
that adverse effects will be noticed as soon as possible, and that any harm that comes
to women and their children provide the benefit of increased scientific knowledge that
can subsequently protect other women and babies from the same harms.
We call for rigorous investigation into possible regulatory violations in this
matter. We also believe that women who have been treated without the protection of
IRBs should now be advised of the information that may not have been made available
to them at the time of treatment, and that they should be given the most recent
information from studies indicating long-term risks to women and children. Finally,
we agree with Dr. Walter Miller, Distinguished Professor of Pediatrics and Chief of
Endocrinology at the University of California San Francisco, who has written that
“this experimental treatment is not warranted and should not be pursued even in
prospective clinical trials.”[9]
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